AVN 67.60 Increased By ▲ 0.50 (0.75%)
BAFL 30.99 Decreased By ▼ -0.01 (-0.03%)
BOP 4.91 Increased By ▲ 0.01 (0.2%)
CNERGY 3.74 Decreased By ▼ -0.04 (-1.06%)
DFML 14.03 Decreased By ▼ -0.40 (-2.77%)
DGKC 41.11 Decreased By ▼ -0.74 (-1.77%)
EPCL 46.58 Increased By ▲ 0.01 (0.02%)
FCCL 11.60 Decreased By ▼ -0.09 (-0.77%)
FFL 5.03 Decreased By ▼ -0.04 (-0.79%)
FLYNG 5.85 Increased By ▲ 0.05 (0.86%)
GGL 10.34 Decreased By ▼ -0.08 (-0.77%)
HUBC 68.04 Increased By ▲ 0.04 (0.06%)
HUMNL 5.74 Decreased By ▼ -0.02 (-0.35%)
KAPCO 28.02 Decreased By ▼ -0.08 (-0.28%)
KEL 2.26 Decreased By ▼ -0.03 (-1.31%)
LOTCHEM 25.02 Decreased By ▼ -0.03 (-0.12%)
MLCF 21.45 Decreased By ▼ -0.24 (-1.11%)
NETSOL 87.66 Increased By ▲ 1.66 (1.93%)
OGDC 99.30 Increased By ▲ 6.92 (7.49%)
PAEL 11.00 Decreased By ▼ -0.09 (-0.81%)
PIBTL 4.26 Increased By ▲ 0.02 (0.47%)
PPL 81.12 Increased By ▲ 0.97 (1.21%)
PRL 13.23 Decreased By ▼ -0.41 (-3.01%)
SILK 0.88 Decreased By ▼ -0.02 (-2.22%)
SNGP 43.85 Increased By ▲ 0.38 (0.87%)
TELE 6.12 Increased By ▲ 0.16 (2.68%)
TPLP 15.66 Decreased By ▼ -0.07 (-0.45%)
TRG 118.99 Increased By ▲ 3.98 (3.46%)
UNITY 14.01 Increased By ▲ 0.16 (1.16%)
WTL 1.23 Increased By ▲ 0.07 (6.03%)
BR100 4,171 Increased By 47 (1.14%)
BR30 15,253 Increased By 323.5 (2.17%)
KSE100 41,523 Increased By 332 (0.81%)
KSE30 15,663 Increased By 168.9 (1.09%)
Follow us

Elon Musk said on Wednesday he expects a wireless brain chip developed by his company Neuralink to begin human clinical trials in six months, after the company missed earlier timelines set by him.

The company is developing brain chip interfaces that it says could enable disabled patients to move and communicate again, with Musk adding on Wednesday that it will also target restoring vision.

Based in the San Francisco Bay Area and Austin, Texas, Neuralink has in recent years been conducting tests on animals as it seeks approval from the US Food and Drug Administration (FDA) to begin clinical trials in people.

“We want to be extremely careful and certain that it will work well before putting a device into a human,” Musk said during a much-awaited public update on the device.

Speaking to a crowd of select invitees in a presentation at Neuralink headquarters that lasted nearly three hours, Musk emphasized the speed at which the company is developing its device.

“The progress at first, particularly as it applies to humans, will seem perhaps agonizingly slow, but we are doing all of the things to bring it to scale in parallel,” he added. “So, in theory, progress should be exponential.”

The FDA did not immediately reply to a Reuters’ request for comment. The first two human applications targeted by the Neuralink device will be in restoring vision and enabling movement of muscles in people who cannot do so, Musk said.

“Even if someone has never had vision, ever, like they were born blind, we believe we can still restore vision,” he said. The event was originally planned for Oct. 31 but Musk postponed it just days before without giving a reason.

Neuralink’s last public presentation, more than a year ago, involved a monkey with a brain chip that played a computer game by thinking alone.

Musk, who also runs electric vehicle manufacturer Tesla , rocket firm SpaceX, and social media platform Twitter, is known for lofty goals such as colonizing Mars and saving humanity.

His ambitions for Neuralink, which he launched in 2016, are of the same grand scale.

EU warns Musk that Twitter must obey disinfo rules

He wants to develop a chip that would allow the brain to control complex electronic devices and eventually allow people with paralysis to regain motor function and treat brain diseases such as Parkinson’s, dementia and Alzheimer’s.

He also talks of melding the brain with artificial intelligence. Neuralink, however, is running behind schedule.

Musk said in a 2019 presentation he was aiming to receive regulatory approval by the end of 2020.

He then said at a conference in late 2021 that he hoped to start human trials this year.

Neuralink has repeatedly missed internal deadlines to gain FDA approval to start human trials, current and former employees have said.

Musk approached competitor Synchron earlier this year about a potential investment after he expressed frustration to Neuralink employees about their slow progress, Reuters reported in August.

Synchron crossed a major milestone in July by implanting its device in a patient in the United States for the first time.

It received US regulatory clearance for human trials in 2021 and has completed studies in four people in Australia.

Comments

Comments are closed.

Elon Musk expects Neuralink’s brain chip to begin human trials in 6 months

Rupee falls 0.35%, settles at 276.28 against US dollar

Government postpones All Parties Conference again as PM will be in Turkiye

KSE-100 rises 0.81% on optimism over resolution of gas sector circular debt

Up to $5mn smuggled into Afghanistan from Pakistan daily: report

PM Shehbaz orders establishment of relief fund to aid Turkiye

Debt reprofiling viable option for Pakistan under IMF watch: report

Adani-owned NDTV's profit more than halves on advertising drop

US trade deficit widens in 2022 to record on strong imports

Islamabad court rejects Sheikh Rashid’s bail petition

Former president Pervez Musharraf laid to rest in Karachi: ISPR